Potential protective properties of a stable, slow-releasing nitric oxide donor, GEA 3175, in the lung

Cardiovascular Drug Reviews

Volumn 24, Issue 3-4, 2006, Pages 247-260

  Laursen, Britt Elmedal ^a   Stankevicius, Edgaras ^a   Pilegaard, Hans ^b   Mulvany, Michael ^a   Simonsen, Ulf ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bronchioles; Calcium activated K+ channels; GEA 3175; Guanylyl cyclase; Na+K+ ATPase; No donors; Pulmonary arteries

Indexed keywords

2 (2 CHLORO 3 METHYLPHENYL) 5 (3 CYCLOHEXYLUREIDO)[1,2,3,4]OXATRIAZOL 3 IUM; 3 (3 CHLORO 2 METHYLPHENYL) 5 (4 METHYLBENZENESULFONYLIMINO) 1,2,3,4 OXATRIAZOLE; 3 (3,4 DICHLOROPHENYL) 1,2,3,4 OXATRIAZOLE 5 IMINE; ADENOSINE; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; CALCIMYCIN; CYCLIC GMP; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GEA 3246; GLYCERYL TRINITRATE; HYDROXIDE; IMINE; LEUKOTRIENE B4; LINSIDOMINE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; OVALBUMIN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SODIUM CHLORIDE; SUPEROXIDE; THROMBIN; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; BRONCHODILATING AGENT; TRIAZOLE DERIVATIVE; VASODILATOR AGENT;

AIRWAY; ALLERGIC ASTHMA; ARTERIAL PRESSURE; BLOOD PRESSURE REGULATION; BRONCHIOLE; BRONCHODILATATION; BRONCHOSPASM; BRONCHUS; CALCIUM CELL LEVEL; CELL ADHESION; CHEMOPROPHYLAXIS; CHEMOTAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; COW; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; EXPERIMENTAL RAT; GUINEA PIG; HEPATOMEGALY; HUMAN; IN VIVO STUDY; ISOLATED ORGAN; LUNG BLOOD VESSEL; NEUTROPHIL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; SLOW DRUG RELEASE; SYNTHESIS; THROMBOCYTE AGGREGATION INHIBITION; TRACHEA; UMBILICAL VEIN; UPREGULATION; VASODILATATION; ANIMAL; LUNG; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; HUMANS; LUNG; NITRIC OXIDE DONORS; PLATELET AGGREGATION INHIBITORS; PULMONARY ARTERY; TRIAZOLES; VASODILATOR AGENTS;

EID: 33847791804     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2006.00247.x     Document Type: Review

References (55)

1. Alanko J, Sievi E, Lahteenmaki T, Mucha I, Riutta A, Vapaatalo H. Effects of NO-donors, SIN-1 and GEA 3175 on prostacyclin and cGMP synthesis in cultured rat endothelial cells. Agents Actions Suppl 1995;45:195-199.
2. Asplund PA, Zalavary S, Lindstrom E, Whiss PA, Bengtsson T, Grenegard M. Cross-talk between adenosine and the oxatriazole derivative GEA 3175 in platelets. Eur J Pharmacol 2005;517(3):149-157.
3. Bannenberg G, Xue J, Engman L, Cotgreave I, Moldeus P, Ryrfeldt A. Characterization of bronchodilator effects and fate of S-nitrosothiols in the isolated perfused and ventilated guinea pig lung. J Pharmacol Exp Ther 1995;272(3):1238-1245.
4. Barnes PJ. Pharmacology of airway smooth muscle. Am J Respir Crit Care Med 1998;158(5,Pt 3): S123-S132.
5. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334(5):296-302.
6. Belvisi MG, Stretton D, Barnes PJ. Nitric oxide as an endogenous modulator of cholinergic neurotransmission in guinea-pig airways. Eur J Pharmacol 1991;198(2-3):219-221.
7. Cases E, Vila JM, Medina P, Aldasoro M, Segarra G, Lluch S. Increased responsiveness of human pulmonary arteries in patients with positive bronchodilator response. Br J Pharmacol 1996;119(7):1337-1340.
8. Chopra LC, Hucks D, Twort CH, Ward JP. Effects of protein tyrosine kinase inhibitors on contractility of isolated bronchioles of the rat. Am J Respir Cell Mol Biol 1997;16(4):372-378.
9. Corell T, Pedersen SB, Lissau B, et al. Pharmacology of mesoionic oxatriazole derivatives in blood, cardiovascular and respiratory systems. Pol J Pharmacol 1994;46(6):553-566.
10. Dupuy PM, Shore SA, Drazen JM, Frostell C, Hill WA, Zapol WM. Bronchodilator action of inhaled nitric oxide in guinea pigs. J Clin Invest 1992;90(2):421-428.
11. Elmedal B, Dam MY, Mulvany MJ, Simonsen U. The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats. Br J Pharmacol 2004;141(1):105-113.
12. Elmedal B, Mulvany MJ, Simonsen U. Dual impact of a nitric oxide donor, GEA 3175, in human pulmonary smooth muscle. Eur J Pharmacol 2005;516(1):78-84.
13. + ATPase in relaxations of bovine isolated bronchioles induced by GEA 3175, an NO donor. Pulm Pharmacol Ther 2005;19(3):179-188.
14. Gaston B, Drazen JM, Loscalzo J, Stamler JS. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994;149(2,Pt 1):538-551.
15. Grenegard M, Gustafsson MC, Andersson RG, Bengtsson T. Synergistic inhibition of thrombin-induced platelet aggregation by the novel nitric oxide-donor GEA 3175 and adenosine. Br J Pharmacol 1996;118(8): 2140-2144.
16. Gruetter CA, Childers CE, Bosserman MK, Lemke SM, Ball JG, Valentovic MA. Comparison of relaxation induced by glyceryl trinitrate, isosorbide dinitrate, and sodium nitroprusside in bovine airways. Am Rev Respir Dis 1989;139(5):1192-1197.
17. Hernandez M, Elmedal B, Mulvany MJ, Simonsen U. Mechanisms of relaxations of bovine isolated bronchioles by the nitric oxide donor, GEA 3175. Br J Pharmacol 1998;123(5):895-905.
18. Hogman M, Wei SZ, Frostell C, Arnberg H, Hedenstierna G. Effects of inhaled nitric oxide on methacholine-induced bronchoconstriction: A concentration response study in rabbits. Eur Respir J 1994;7(4): 698-702.
19. Holm P, Kankaanranta H, Metsa-Ketela T, Moilanen E. Radical releasing properties of nitric oxide donors GEA 3162, SIN-1 and S-nitroso-N- acetylpenicillamine. Eur J Pharmacol 1998;346(1):97-102.
20. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351(14):1425-1436.
21. Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004;1(3):176-183.
22. Johansson RI, Andersson RG, Grenegard M. Effects of the nitric oxide-donor, GEA 3175, on guinea-pig airways. Eur J Pharmacol 1997;329(2-3):175-180.
23. Kacmarek RM, Ripple R, Cockrill BA, Bloch KJ, Zapol WM, Johnson DC. Inhaled nitric oxide. A bronchodilator in mild asthmatics with methacholine-induced bronchospasm. Am J Respir Crit Care Med 1996;153(1):128-135.
24. Kankaanranta H, Rydell E, Petersson AS, et al. Nitric oxide-donating properties of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives. Br J Pharmacol 1996;117(3):401-406.
25. Karup G, Preikschat H, Wilhelmsen ES, et al. Mesoionic oxatriazole derivatives - a new group of NO-donors. Pol J Pharmacol 1994;46(6):541-552.
26. Karup GL, Preitscak HF, Corell T, et al. WO Patent 92/13847.1992.
27. Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing nonsteroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 2002;137(3):295-310.
28. Kharitonov SA, Barnes PJ. Nitric oxide, nitrotyrosine, and nitric oxide modulators in asthma and chronic obstructive pulmonary disease. Curr Allergy Asthma Rep 2003;3(2):121-129.
29. Kosonen O, Kankaanranta H, Lahde M, Vuorinen P, Ylitalo P, Moilanen E. Nitric oxide-releasing oxatriazole derivatives inhibit human lymphocyte proliferation by a cyclic GMP-independent mechanism. J Pharmacol Exp Ther 1998;286(1):215-220.
30. Kosonen O, Kankaanranta H, Malo-Ranta U, Moilanen E. Nitric oxide-releasing compounds inhibit neutrophil adhesion to endothelial cells. Eur J Pharmacol 1999;382(2):111-117.
31. Kosonen O, Kankaanranta H, Malo-Ranta U, Ristimaki A, Moilanen E. Inhibition by nitric oxide-releasing compounds of prostacyclin production in human endothelial cells. Br J Pharmacol 1998;125(2):247-254.
32. Kosonen O, Kankaanranta H, Uotila J, Moilanen E. Inhibition by nitric oxide-releasing compounds of E-selectin expression in and neutrophil adhesion to human endothelial cells. Eur J Pharmacol 2000;394(1):149-156.
33. Kosonen O, Kankaanranta H, Vuorinen P, Moilanen E. Inhibition of human lymphocyte proliferation by nitric oxide-releasing oxatriazole derivatives. Eur J Pharmacol 1997;337(1):55-61.
34. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005;258(3):199-215.
35. 2+ entry. J Biol Chem 1999;274(50):35318-35324.
36. Mehta S, Stewart DJ, Langleben D, Levy RD. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 1995;92(6):1539-1545.
37. Mitani Y, Maruyama K, Sakurai M. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation 1997;96(2):689-697.
38. Moilanen E, Vuorinen P, Kankaanranta H, Metsa-Ketela T, Vapaatalo H. Inhibition by nitric oxide-donors of human polymorphonuclear leucocyte functions. Br J Pharmacol 1993;109(3):852-858.
39. Moncada S, Higgs EA. Endogenous nitric oxide: Physiology, pathology and clinical relevance. Eur J Clin Invest 1991;21(4):361-374.
40. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43(2):109-142.
41. Moreno RH, Hogg JC, Pare PD. Mechanics of airway narrowing. Am Rev Respir Dis 1986;133(6):1171-1180.
42. Napoli C, Ignarro LJ. Nitric oxide-releasing drugs. Annu Rev Pharmacol Toxicol 2003;43:97-123.
43. Nicosia S, Capra V, Rovati GE. Leukotrienes as mediators of asthma. Pulm Pharmacol Ther 2001; 14(1):3-19.
44. Paakkari I, Nevala R, Peitola A, Vapaatalo H. Effect of nitric oxide donors on rat bronchial muscle in vitro. Agents Actions Suppl 1995;45:207-211.
45. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2(8567):1057- 1058.
46. Redington AE. Modulation of nitric oxide pathways: Therapeutic potential in asthma and chronic obstructive pulmonary disease. Eur J Pharmacol 2006;533(1-3):263-276.
47. Schindler MB, Bohn DJ, Bryan AC, Cutz E, Rabinovitch M. Increased respiratory system resistance and bronchial smooth muscle hypertrophy in children with acute postoperative pulmonary hypertension. Am J Respir Crit Care Med 1995;152(4,Pt 1):1347-1352.
48. Schonafinger K. Heterocyclic NO prodrugs. Farmaco 1999;54(5):316-320.
49. Snetkov VA, Hapgood KJ, McVicker CG, Lee TH, Ward JP. Mechanisms of leukotriene D4-induced constriction in human small bronchioles. Br J Pharmacol 2001;133(2):243-252.
50. + channel. Exp Physiol 1999;84(5):835-846.
51. Asplund Persson AK, Palmer L, Gunnarsson P, Grenegard M. Characterisation of GEA 3175 on human platelets; comparison with S-nitroso-N-acetyl-D,L- penicillamine. Eur J Pharmacol 2004;496(1-3):1-9.
52. Stasch JP, Schmidt P, Alonso-Alija C, et al. NO- and haem-independent activation of soluble guanylyl cyclase: Molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002;136(5):773-783.
53. Taylor EL, Rossi AG, Shaw CA, Dal Rio FP, Haslett C, Megson IL. GEA 3162 decomposes to co-generate nitric oxide and superoxide and induces apoptosis in human neutrophils via a peroxynitrite-dependent mechanism. Br J Pharmacol 2004;143(1):179-185.
54. Ward JK, Barnes PJ, Tadjkarimi S, Yacoub MH, Belvisi MG. Evidence for the involvement of cGMP in neural bronchodilator responses in humal trachea. J Physiol 1995;483(Pt 2):525-536.
55. Whiss PA, Larsson R. Adenosine 5′-diphosphate-induced platelet aggregation in uremia shows resistance to inhibition by the novel nitric oxide donor GEA 3175 but not by S-nitroso-N-acetylpenicillamine. Haemostasis 1998;28(5):260-267.